Procter & Gamble guidance
This article was originally published in The Rose Sheet
Executive Summary
Third quarter and fiscal year earnings per share are expected to exceed current estimates by $0.01-$0.02 per share, driven by strong volume and sales growth, firm says. Organic sales growth in the third quarter is anticipated to rise 10%, with total sales increasing 20%, according to P&G. Favorable currency will increase sales 3%-4%, while acquisitions including Wella will add 7%-9%, the company predicts. Top line performance will be driven in part by innovations in Olay Regenerist, Crest Whitening Expressions, as well as international expansion of Herbal Essences, P&G adds. Firm also announces two-for-one stock split will occur May 21 in form of 100% stock dividend. P&G will report third quarter results April 30...
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.